Tuesday, November 17, 2015
The FDA has granted Accelerated Approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) now is approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
Arxspan, a cloud-based solutions provider based in Massachusetts, has entered into an agreement with the Broad Institute of MIT and Harvard for use of its ArxLab cloud-based suite of biological and chemical discovery information management tools. The partnership will support the institute’s efforts to electronically manage and share both biological and chemical research information internally and with external collaborators. The ArxLab suite of tools will be used for managing the institute’s electronic laboratory notebook, compound and assay registration, scientific analysis and search, biological visualization, and inventory management functions.
Next Bio-Research Services has officially began operations in the Ironbridge Medical Park in Chester, Va. The company continues a 23-year history of providing comprehensive integrated project support to investigators in the biotech and pharmaceutical sectors and in providing medical testing services to physicians using state-of-the-art platforms.